Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes;Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2

Medicina Clinica

Volumn 141, Issue SUPPL. 2, 2013, Pages 36-43

  Albarrán, Olga González ^a   Ampudia Blasco, F Javier ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Clinical trials; Dapagliflozin; Efficacy; Safety; SGLT2 inhibitors; Sodium glucose co transporters; Tolerability; Type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE;

ARTICLE; DIABETIC PATIENT; DRUG APPROVAL; DRUG MECHANISM; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT REDUCTION;

CLINICAL TRIALS; COTRANSPORTADORES DE SODIO-GLUCOSA; DAPAGLIFLOZIN; DAPAGLIFLOZINA; DIABETES TIPO 2; EFFICACY; EFICACIA; ESTUDIOS CLÍNICOS; GLUCOSÚRICOS; INHIBIDORES DE SGLT2; SAFETY; SEGURIDAD; SGLT2 INHIBITORS; SODIUM-GLUCOSE CO-TRANSPORTERS; TOLERABILITY; TOLERANCIA; TYPE 2 DIABETES;

BIOLOGICAL TRANSPORT, ACTIVE; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; GLUCOSE; GLUCOSIDES; GLYCOSURIA; HALF-LIFE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MOLECULAR STRUCTURE; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; WEIGHT LOSS;

EID: 84893043625     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(13)70062-9     Document Type: Article

References (32)

1. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55:88-93.
2. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136-42.
3. Gerich JE, Bastien A. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2011;4:669-83.
4. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272-7.
5. Bishop JH, Green R, Thomas S. Free-flow reabsorption of glucose, sodium, osmoles and water in rat proximal convoluted tubule. J Physiol. 1979;288:331-51.
6. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723-9.
7. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Durg Metab Dispos. 2010;38:405-14.
8. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
9. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-9.
10. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51: 1145-9.
11. Kasichayanula S, Liu X, Shyu WC, Zhang W, Pfister M, Griffen SC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13:47-54.
12. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7. Dapagliflozin (Forxiga): EU summary of product characteristics [online].
13. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double- blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24.
14. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozina in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet. 2010;375:2223-33.
15. Bailey CJ, Iqbal N, TJoen C, List JE. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized- controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951-9.
16. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozina in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928-38.
17. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodiumglucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-8.
18. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-15.
19. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care. 2011;34: 2015-22.
20. Nauck M, Del Prato S, Durán-García S, Rohwedder K, Theuerkauf A, Langkilde AM, et al. Durability of glycemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin. Diabetes Care. [Submitted, June 2013].
21. Del Prato S, Nauck MA, Durán-García S, Rohwedder K, Theuerkauf A, Langkilde AM, et al. Durability of dapagliflozin vs glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data. 73 Scientific Sessions ADA. 2013, June. Abstract 62-LB.
22. Wilding JPH, Woo V, Rohwedder K, Sugg J, Parikh SJ, for the Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2013 Aug 1. doi: 10.1111/dom.12187. [Epub ahead of print].
23. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446-56.
24. Bailey CJ, Gross JL, Hennicken D, Isqal N, Mansfield TA, List JF. Dapagliflozin add on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102 week trial. BMJ. 2013;11:43.
25. Bailey CJ, Wilding J, Nauck MA. Sustained reductions in weight and HbA1c with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes [abstract n. 721]. European Association for the Study of Diabetes. Berlin; 2012 Oct 1-5. Abstract 721.
26. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozina on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-3.
27. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. Diabetes Complications. 2013. [Epub ahead of print].
28. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.J Diabetes Complications. 2013. [Epub ahead of print].
29. Johnsson K, Ptaszynska A, Apanovitch A, Sugg J, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus. European Association for the Study of Diabetes. Berlin; 2012 Oct 1-5. Abstract 743 + poster.
30. Ptaszynska A, Chalamandaris A-G, Sugg J, Parikh SJ, List JF. Dapagliflozin does not impact renal function in patients with type 2 diabetes. European Association for the Study of Diabetes. Berlin; 2012 Oct 1-5. Abstract 242.
31. Ptaszynska A, Johnsson KM, Apanovitch AM, Sugg JE, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for T2DM. 72nd Annual Meeting of the American Diabetes Association. Philadelphia (PA); 2012 Jun 8-12. Abstract 1011-P.
32. Parikh SJ, et al. 71st ADA Scientific Sessions, San Diego, June 24-28, 2011 [abstract 984-P].